Lawsuits Against Medicare Drug Negotiations Are Mounting, But They Probably Won’t Be Able to Stop The Plan

MedCity News June 26, 2023
Katie Adams

Lawsuits filed in opposition to the White House’s drug pricing negotiation program are beginning to mount, but legal experts agree that the plaintiffs’ arguments probably won’t hold up during a court battle. However, these lawsuits still could delay when the government’s ability to negotiate price goes into effect.

Earlier this month, Merck became the first entity to legally challenge the White House’s Medicare drug pricing negotiation program. Since then, three more lawsuits have been filed in opposition to the program. While legal experts agree that the plaintiffs’ arguments probably won’t hold up during a court battle, these lawsuits still could delay when the government’s ability to negotiate price goes into effect.

HHS and CMS are currently facing four drug pricing...

Today's Sponsors

Today's Sponsor